Zentalis Pharmaceuticals, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Zentalis Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Zentalis Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$51.4M, a 18% increase year-over-year.
  • Zentalis Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$209M, a 26.1% increase year-over-year.
  • Zentalis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$300M, a 31.8% decline from 2022.
  • Zentalis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$227M, a 4.96% decline from 2021.
  • Zentalis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$217M, a 82.3% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$300M -$72.2M -31.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 -$227M -$10.7M -4.96% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 -$217M -$97.8M -82.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 -$119M -$71.9M -154% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$46.8M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.